January 19, 2012 — Multisite cryoablation of metastatic epithelial ovarian cancer is well tolerated, has a 5-year overall survival rate of 30%, and is cost effective, compared with other forms of ...

While offering advantages like faster recovery and high patient satisfaction, cryoablation for the treatment of early-stage breast cancer is still under investigation for effectiveness and requires ...

Cryoablation is a fairly new treatment being used to treat small cancer tumors. Could we soon see it offered as an alternative to traditional breast cancer surgeries? There isn’t a day that goes by ...

"For patients who have larger tumors but can't undergo surgery, this approach could be more effective," interventional radiologist Yolanda Bryce, M.D. said Getty Breast cancer patients who were ...

Five-year recurrence-free rates of 89.4% and 83.9% indicate durable disease control after ProSense cryoablation in localized small renal masses, supporting its role as a surgery-sparing local ...

Please provide your email address to receive an email when new articles are posted on . Cryoablation may be an effective primary treatment option for women with low-risk breast cancer, according to ...

IceCure Medical Ltd ICCM recently announced that it has received marketing authorization from the FDA for its next-generation single probe cryoablation system, XSense Cryoablation System with ...

Women with early-stage breast cancer who couldn't enter clinical trials of cryoablation because of "unfavorable" tumor or patient characteristics nevertheless enjoyed a high rate of treatment success ...

ORLANDO -- Cryoablation without excision for low-risk, early-stage breast cancer may be an option for women over 60, 5-year follow-up results from the ICE3 trial showed. At a mean follow-up of 54.2 ...

7-partial-nephrectomy-0516 Among patients with pT1b renal cell carcinoma, cryoablation is associated with a 2.5-fold higher 5-year cancer-specific mortality rate compared with partial nephrectomy, a ...

Use of the ProSense Cryoablation System in patients with kidney cancer resulted in an 83.9% recurrence-free rate among 112 ...